Scott Kopetz
YOU?
Author Swipe
View article: Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis
Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis Open
Recurrent liver‐metastatic colorectal cancer contributes to high mortality. Recurrence occurs when dormant, microscopic residual disease survives initial treatment to escape dormancy. In their dormant, microscopic state within the liver, t…
View article: Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer Open
Nivolumab alone and in combination with ipilimumab demonstrated durable clinical benefit in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer in the phase 2 CheckMate 14…
View article: Supplementary Methods from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Supplementary Methods from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Supplementary Methods
View article: Table 2 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table 2 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Contingency table comparing BRAFV600E status between the CTA and F1LCDx
View article: Table S5. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S5. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Summary statistics of estimated log(HR) and ORR difference for the F1LCDx+/CTA+ population (𝜹𝟏) on imputed complete data.
View article: Table S2. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S2. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Plasma sample sizes and sources for LBx testing.
View article: Table S4. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S4. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Summary statistics of PPA and PPV after including imputed data.
View article: Table S1. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S1. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Representativeness of the patient population analyzed.
View article: Figure 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Figure 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Sample processing flow chart. LC, library construction; QC, quality control; SEQ, sequencing. aData from these samples are not included in this study. bPlasma sample was not available for testing with LBx. c
View article: Table 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Demographics and clinical characteristics in the LBx test-evaluable and -unevaluable subsets
View article: Data from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Data from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Purpose:The BRAF inhibitor encorafenib (Enco) plus the anti-EGFR antibody cetuximab (Cetux) improved overall survival, objective response rate, and progression-free survival in previously treated BRAFV600E-mutant metastat…
View article: Table 4 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table 4 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Primary efficacy in the bridging study subpopulations
View article: Table S3. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S3. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Tumor fraction in F1LCDx−/CTA+ and F1LCDx+/CTA− subsets.
View article: Table 3 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table 3 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Concordance analysis results
View article: Table S6. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S6. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Estimated efficacy for the F1LCDx+ population in the sensitivity analysis.
View article: Cooperativity between Ras pathway mutations in colonic tumorigenesis
Cooperativity between Ras pathway mutations in colonic tumorigenesis Open
The Kirsten rat sarcoma ( KRAS ) gene is the most frequently mutated oncogene in colorectal cancer (CRC). We previously characterized two activating alleles of KRAS , A59T and A59E, that show impaired BRAF dimerization. These alleles of KR…
View article: Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i> V600E in Colorectal Cancer
Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i> V600E in Colorectal Cancer Open
Purpose: The BRAF inhibitor encorafenib (Enco) plus the anti-EGFR antibody cetuximab (Cetux) improved overall survival, objective response rate, and progression-free survival in previously treated BRAFV600E-mutant metastatic colorectal can…
View article: Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer Open
Objective: In this study, we evaluate the utility of ctDNA analysis in a large cohort of patients for whom ctDNA testing was ordered commercially with real-world application. Summary Background Data: Circulating tumor DNA (ctDNA) has emerg…
View article: 1O Precemtabart tocentecan (M9140): Initial results from the phase I PROCEADE-CRC-01 dose optimization study and preclinical antitumor activity across tumor models
1O Precemtabart tocentecan (M9140): Initial results from the phase I PROCEADE-CRC-01 dose optimization study and preclinical antitumor activity across tumor models Open
View article: Proteotranscriptomic Analyses of Microsatellite-Stable Early-Onset Colorectal Cancer
Proteotranscriptomic Analyses of Microsatellite-Stable Early-Onset Colorectal Cancer Open
PURPOSE The prevalence and death rates of early-onset colorectal cancer (EOCRC) have been increasing at an alarming rate since 1994. Compared with late-onset colorectal cancer (LOCRC), EOCRC is more aggressive and resistant to treatment. D…
View article: Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial Open
View article: Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers Open
The therapeutic benefit of recently developed mutant KRAS (KRAS∗) inhibitors remains limited by the rapid onset of resistance. Here, we aim to delineate mechanisms underlying acquired resistance and identify actionable targets for overcomi…
View article: Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach
Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach Open
Among patients with advanced CRC, partner-agnostic ctDNA fusion detection is possible and improves identification as a blood-based approach by extension of fusion calling partners. Detection of fusions in the ctDNA may provide rationale fo…
View article: Figure S6 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Figure S6 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations Open
Figure S6 shows the basal levels of protein expression and phosphorylation in a set of PDAC cell lines, determined by Western blot, and the Western blot analysis of the signaling response to RMC-7977 in AsPC-1 and HS766.T, grown in regular…
View article: Figure S1 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Figure S1 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations Open
Figure S1 shows the dose-response curves of RMC-7977 in a panel of human cancer cell lines harboring mutations in RAS and belonging to three different lineages.
View article: Data from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Data from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations Open
RAS genes are frequently mutated in cancer, often at codons 12 and 61. With the recent introduction of RAS inhibitors, we can now directly investigate the effects of specific RAS mutations in cancer cells. In this study, we demonstr…
View article: Figure S2 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Figure S2 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations Open
Figure S2 shows the dose-response Western blot analysis of MIA PaCa-2 treated with different concentrations of RMC-7977 for 1h and 24h, the Western blot analysis of early signaling dynamics following treatment with trametinib in six repres…
View article: Figure S10 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Figure S10 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations Open
Figure S10 shows the pulldown of GTP-bound RAS in PANC-1 and SW480 treated with DMSO, RMC-7977 (10nM), Cetuximab (25μg/mL), or their combination for 24 hours, and the dose-response pharmacology assay of AsPC-1 cells treated with different …
View article: Figure S4 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Figure S4 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations Open
Figure S4 shows the Western blot analysis of the MAPK and PI3K pathway responses to RMC-7977, trametinib, alpelisib 1μM / AZD-8186, and the respective combinations in COLO678 and Sk-Mel-176, and the drug combination validation experiments …
View article: Figure S3 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Figure S3 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations Open
Figure S3 shows the Western blot analysis of early signaling dynamics following treatment with trametinib in two HTVI-KRAS G12D and two HTVI-KRAS Q61R lines.